Navigation Links
Chiltern Welcomes Drs. Dieter Seitz-Tutter And Alexandra Adams
Date:9/10/2012

LONDON, Sept. 10, 2012 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced that Drs. Dieter Seitz-Tutter and Alexandra Adams have joined Chiltern, bringing their extensive expertise in clinical research to serve our clients' needs and to strengthen our Global Clinical Development service.

"It gives me great pleasure to announce that Dieter Seitz-Tutter, Ph.D. has been appointed to the new role of Vice President, Global Clinical Development, Europe," stated Aize Smink, Sr. Executive VP, Global Clinical Development, Chiltern. "Dr. Seitz-Tutter will lead Chiltern's Global Clinical Development business across Europe, comprising Clinical Operations and Project Management which is experiencing strong growth thanks to deeper client relations and demand for our quality services."

Recently joining Chiltern is Alexandra Adams, Ph.D. as Director, Late Phase, Europe. "Dr. Adams will lead the Global Late Phase Group in Europe which is focused on implementing tailored solutions for late phase studies and registries in a cost effective way on behalf of our client base," commented Steve Albrecht, Global Head, Late Phase, Chiltern.

Dr. Seitz-Tutter has more than 22 years experience in the clinical research field which he gained from various senior roles in both Pharma and CROs, most recently serving as Vice President Europe with a global corporation. Dr. Seitz-Tutter holds a Master's degree and a doctorate in Biology from the University of Munich, Germany, and is also based out of Munich.

Dr. Adams brings 25 years experience from a varied background in both Pharma and CRO positions. Her experience includes developing new procedures and strategies for the implementation of non-interventional studies. Dr. Adams received her Ph.D. in Biochemistry / Pharmacology from the Cardiothoracic Institute at the University of London. She is a long-standing member of the Institute of Clinical Research, having served on the Board of Directors and in the position of Treasurer. Dr. Adams is based out of Slough, UK.

Company profileAbout Chiltern:Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs nearly 1,400 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. Further information is available at: www.chiltern.com.

For More Information Contact:Natalie Chong

Susan OjanenMarketing Director

Marketing ExecutiveChiltern International Ltd.

Chiltern International Inc.171 Bath Road

1241 Volunteer ParkwaySlough

Suite 950Berkshire SL1 4AA

Bristol, TN 37620UNITED KINGDOM

USATel:  +44 (0) 1753 512 000

Tel:  +1 (423) 968 9533Fax: +44 (0) 1753 511 116

Fax: +1 (423) 968 3567Email: natalie.chong@chiltern.com

Email: susan.ojanen@chiltern.com


'/>"/>
SOURCE Chiltern
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Chiltern Announces New Legal Entity In Taiwan
2. United States Rocket Academy Welcomes XCOR Aerospace to Texas
3. Agendia Welcomes Dr. Mark Gittleman to Expanding Medical Advisory Board
4. The 14th Annual LOréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrows Scientific Talents
5. Cepheid Welcomes Senior Vice President of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... -- According to a new market report published ... A Streptococcus (GAS) Nucleic Acid (NA) Test Products Market - ... - 2023 ", the Europe molecular ... test products market was valued at US$ 8.3 Mn in ... 11.6% from 2015 to 2023 to reach US$ 22.3 Mn ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... release, Clinical Studio Version 4.1, greatly improves performance of the platform. In particular, ... often generate tremendous volumes of data to be collected on a per patient ...
(Date:5/5/2016)... ... 2016 , ... Proove Biosciences, Inc. today announced ... diagnostics company. The Algynomics platform and its patient cohorts provide researchers ... chronic pain, which will allow targeted preventive efforts, enhance patient stratification in clinical ...
(Date:5/5/2016)...  Why are two uber-successful former agency presidents ... launching a new venture—yet going about things in a ... helping clients raise the value of their offerings in ... type of collaboration. The result is Elevate, ... medical device sectors. Elevate specializes in shaping and transforming ...
Breaking Biology Technology:
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
(Date:3/17/2016)... , March 17, 2016 ABI ... intelligence, forecasts the global biometrics market will reach ... impressive 118% increase from 2015. Consumer electronics, particularly ... embedded fingerprint sensors anticipated to reach two billion ... Dimitrios Pavlakis , Research Analyst at ...
(Date:3/11/2016)... , March 11, 2016 http://www.apimages.com ) ... Cross reference: Picture is available at AP Images ( http://www.apimages.com ) ... DERMALOG will be used to produce the new refugee identity cards. ... biometric innovations, at CeBIT in Hanover next ... from DERMALOG will be used to produce the new refugee identity ...
Breaking Biology News(10 mins):